**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 12.350

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2018 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431  
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

**Editorial**

- 1095** Disease activity in ankylosing spondylitis: the global therapeutic target  
*D Wendling, C Prati, J Sieper*

**Heroes and pillars of rheumatology**

- 1097** Jacques FORESTIER, a visionary of the clinical epidemiology in rheumatology  
*M Dougados*

**Review**

- 1099** Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis  
*S Hilliquin, B Hugues, S Mitrovic, L Gossec, B Fautrel*

**Clinical and epidemiological research**

- 1107** Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative



*T Constantin, I Foeldvari, J Anton, J de Boer, S Czitrom-Guillaume, C Edelsten, R Gepstein, A Heiligenhaus, C A Pilkington, G Simonini, Y Uziel, S J Vastert, N M Wulffraat, A-M Haasnoot, K Walscheid, A Pálincás, R Pattani, Z Györgyi, R Kozma, V Boom, A Ponyi, A Ravelli, A V Ramanan*

- 1118** Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modelling approach



*E J F Santos, C Duarte, R J O Ferreira, A M Pinto, R Geenen, J A P da Silva, On behalf of the 'Promoting Happiness Through Excellence of Care' Group*

- 1125** The use of MRI-detected synovitis to determine the number of involved joints for the 2010 ACR/EULAR classification criteria for Rheumatoid Arthritis – is it of additional benefit?

*A C Boer, D M Boeters, A H M van der Helm-van Mil*

- 1130** ACPA IgG galactosylation associates with disease activity in pregnant patients with rheumatoid arthritis

*A Bondt, L Hafkenscheid, D Falck, T M Kuijper, Y Rombouts, J M W Hazes, M Wuhrer, R J E M Dolhain*

- 1137** Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis

*M Dubreuil, Q Louie-Gao, C E Peloquin, H K Choi, Y Zhang, T Neogi*

- 1143** Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

*P Charles, B Terrier, É Perrodeau, P Cohen, S Faguer, A Huart, M Hamidou, C Agard, B Bonnotte, M Samson, A Karras, N Jourde-Chiche, F Lifermann, P Gobert, C Hanrotel-Saliou, P Godmer, N Martin-Silva, G Pugnet, M Matignon, O Aumaitre, J-F Viillard, F Maurier, N Meaux-Ruault, S Rivière, J Sibilia, X Puéchal, P Ravaud, L Mouthon, L Guillevin, for the French Vasculitis Study Group*

- 1150** Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides



*B Terrier, C Pagnoux, É Perrodeau, A Karras, C Khouatra, O Aumaitre, P Cohen, O Decaux, H Desmurs-Clavel, F Maurier, P Gobert, T Quémeneur, C Blanchard-Delaunay, B Bonnotte, P-L Caron, E Dugas, M Ducret, P Godmer, M Hamidou, O Lidove, N Limal, X Puéchal, L Mouthon, P Ravaud, L Guillevin, on behalf of the French Vasculitis Study Group*

- 1157** Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire

*J C Robson, J Dawson, H Doll, P F Cronholm, N Milman, K Kellom, S Ashdown, E Easley, D Gebhart, G Lanier, J Mills, J Peck, R A Luqmani, J Shea, G Tomasson, P A Merkel*

- 1165** Comparison of magnetic resonance angiography and <sup>18</sup>F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis

*K A Quinn, M A Ahlman, A A Malayeri, J Marko, A C Civelek, J S Rosenblum, A A Bagheri, P A Merkel, E Novakovich, P C Grayson*

MORE CONTENTS ►



EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008


JMS0004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 1172** Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study  
*G Moulis, G Pugnet, N Costedoat-Chalumeau, A Mathian, G Leroux, J Boutémy, O Espitia, L Bouillet, S Berthier, J-B Gaultier, P-Y Jeandel, A Konaté, A Mékinian, E Solau-Gervais, B Terrier, D Wendling, F Andry, C Garnier, P Cathébras, L Arnaud, A Palmaro, P Cacoub, Z Amoura, J-C Piette, P Arlet, M Lapeyre-Mestre, L Sailler*
- 1179** Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer  
*T Igusa, L K Hummers, K Visvanathan, C Richardson, F M Wigley, L Casciola-Rosen, A Rosen, A A Shah*
- 1187** Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study  
*S F Keller, N Lu, K G Blumenthal, S K Rai, C Yokose, J W J Choi, S C Kim, Y Zhang, H K Choi*
- 1194** Identification of calcium pyrophosphate deposition disease (CPPD) by ultrasound: reliability of the OMERACT definitions in an extended set of joints—an international multiobserver study by the OMERACT Calcium Pyrophosphate Deposition Disease Ultrasound Subtask Force  
*G Filippou, C A Scirè, A Adinolfi, N S Damjanov, G Carrara, G A W Bruyn, T Cazenave, M A D'Agostino, A Delle Sedie, V Di Sabatino, M E Diaz Cortes, E Filippucci, F Gandjbakhch, M Gutierrez, D K MacCarter, M Micu, I Möller Parera, G Mouterde, M A Mortada, E Naredo, C Pineda, F Porta, A M Reginato, I Satulu, W A Schmidt, T Serban, L Terslev, V Vlad, F A Vreju, P Zufferey, P Bozios, C Toscano, V Picerno, A Iagnocco*
- 
- Basic and translational research**
- 1200** Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjögren's syndrome  
*E K Kapsogeorgou, A Papageorgiou, A D Protogerou, M Voulgarelis, A G Tzioufas*
- 1208** Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts  
*Y He, P-S Tsou, D Khanna, A H Sawalha*
- 1219** *In vivo* visualisation of different modes of action of biological DMARDs inhibiting osteoclastic bone resorption  
*Y Matsuura, J Kikuta, Y Kishi, T Hasegawa, D Okuzaki, T Hirano, M Minoshima, K Kikuchi, A Kumanogoh, M Ishii*
- 1226** Metabolic pathways and immunometabolism in rare kidney diseases  
*P C Grayson, S Eddy, J N Taroni, Y L Lightfoot, L Mariani, H Parikh, M T Lindenmeyer, W Ju, C S Greene, B Godfrey, C D Cohen, J Krischer, M Kretzler, P A Merkel, the Vasculitis Clinical Research Consortium, the European Renal cDNA Bank cohort, and the Nephrotic Syndrome Study Network*
- 
- Letters**
- 1234** Shared epitope positivity is related to efficacy of abatacept in rheumatoid arthritis  
*K Oryoji, K Yoshida, Y Kashiwado, K Tanaka, S Mizuki, H Tsukamoto, K Kamada, K Akashi*
- 1236** Seropositivity combined with smoking is associated with increased prevalence of periodontitis in patients with rheumatoid arthritis  
 *K Eriksson, L Nise, L Alfredsson, A I Catrina, J Askling, K Lundberg, L Klareskog, T Yucel-Lindberg*
- 1238** Amount of smoking, duration of smoking cessation and their interaction with silica exposure in the risk of rheumatoid arthritis among males: results from the Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study  
*P Zeng, Z Chen, L Klareskog, L Alfredsson, C Bengtsson, X Jiang*
- 1241** High-dose ustekinumab for severe childhood deficiency of interleukin-36 receptor antagonist (DITRA)  
*N Bonekamp, R Caorsi, G M Viglizzo, M de Graaf, F Minoia, A Grossi, P Picco, I Ceccherini, J Frenkel, M Gattorno*
- 1243** Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults  
*J A Singh, J D Cleveland*
- 1245** 'Twitterland': a brave new world?  
*E Nikiphorou, P Studenic, A Alunno, M Canavan, M Jani, F Berenbaum*
- 
- Electronic pages**
- e47** Discussion of Methotrexate Dosage  
*S A Maguire, C M Sheehy*
- e48** Response to eLetter: 'Discussion of methotrexate dosage' by Maguire *et al*  
*M Safy, J W G Jacobs, N D Ijff, J W J Bijlsma, J M van Laar, M J H de Hair, Society for Rheumatology Research Utrecht (SRU)*
- e49** Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: an updated meta-analysis  
*C M Olsen, A C Green*

- e50** Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria  
*L Cavagna, S Castañeda, C Sciré, M A Gonzalez-Gay, On Behalf of the AENEAS Collaborative Group Members*
- e51** Response to: 'Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria' by Cavagna *et al*  
*J B Lilleker, J Vencovsky, G Wang, L R Wedderburn, L P Diederichsen, J Schmidt, P Jordan, O Benveniste, M G Danieli, K Dankó, N T Phuong Thuy, M V-D Mercado, H Andersson, B D Paepe, J L De Bleecker, B Maurer, L J McCann, N Pipitone, N McHugh, Z Betteridge, P New, R G Cooper, W E Ollier, J A Lamb, N S Krogh, I E Lundberg, H Chinoy, On behalf of all EuroMyositis contributors*
- e52** Obesity and CRP  
*F Aslam*
- e53** Response to: the value of 18(F)-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study  
*V Schönau, G Schett*
- e54** Chondroitin sulfate is superior to placebo in symptomatic knee osteoarthritis  
*Y H Lee*
- e55** Differentiation between various Chondroitin sulfate formulations in symptomatic knee osteoarthritis  
*J Y Reginster*